Under construction – not a live service
Sign in
Taking people in JapanPhase 2

Tests new drug candidates against placebo in adults with moderate to severe atopic dermatitis

Tests GHZ339 against placebo in adults with moderate to severe atopic dermatitis.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Fukuoka, Habikino, Kawasaki, Kyoto, Matsudo, Nagoya, Shinagawa Ku, and Yokohama, JapanSee the 8 sitesAlso in 16 other countries, 96 sites
Registry title
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Status
Recruiting
Phase
Phase 2
People taking part
224 people, planned
Started
16 May 2025
Expected to end
22 Dec 2028
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • GHZ339
  • Placebo
Record updated
28 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe atopic dermatitis (eczema) to test investigational compounds against placebo.

Age
18 to 100 years
Sex
All sexes can join.
Disease stage
Atopic dermatitis that is moderate to severe, with onset at least 1 year ago.

Main reasons for not taking part

  • Clinically significant medical condition or infectious disease (specified in the sub-protocol)
  • Clinically significant abnormal blood, chemistry, urine or ECG results
  • Any other active inflammatory skin disease
  • Chronic, uncontrolled medical condition, such as uncontrolled diabetes or high blood pressure
  • Unstable disease that would likely need systemic corticosteroids, such as uncontrolled asthma

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Able and willing to sign the informed consent (IC)
  • Patients with a diagnosis of AD and onset of disease for at least 1 year
  • Moderate to severe AD

Who cannot take part

  • Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
  • Participant with any other active inflammatory skin disease
  • Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
  • Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma); Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements
  • Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Where in Japan

Also in 16 other countries, 96 sites

  • FukuokaHospital not named in the registryContact: Novartis PharmaceuticalsNo longer taking part
  • Habikino, OsakaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Kawasaki, KanagawaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • KyotoHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Matsudo, ChibaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Nagoya, Aichi-kenHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Shinagawa Ku, TokyoHospital not named in the registryContact: Novartis PharmaceuticalsNo longer taking part
  • Yokohama, KanagawaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people

About the trial

What the trial wants to find out

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

The 5 groups in the trial

  • GHZ339 Dose ATreatment being tested

    Participants who will receive GHZ339 at dose A during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2

    Treatment: GHZ339

  • GHZ339 Dose BTreatment being tested

    Participants who will receive GHZ339 at dose B during Treatment Period 1 will receive GHZ339 at dose B during Treatment Period 2

    Treatment: GHZ339

  • GHZ339 Dose CTreatment being tested

    Participants who will receive GHZ339 at dose C during Treatment Period 1 will receive GHZ339 at dose C or A during Treatment Period 2

    Treatment: GHZ339

  • GHZ339 Dose DTreatment being tested

    Participants who will receive GHZ339 at dose D during Treatment Period 1 will receive GHZ339 at dose D or A during Treatment Period 2

    Treatment: GHZ339

  • PlaceboPlacebo, for comparison

    Participants who will receive placebo during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2

    Treatment: GHZ339 and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Plain-language title
Tests new drug candidates against placebo in adults with moderate to severe atopic dermatitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06947993, who can take part
Record updated
28 September 2026